Rupali Roy Bhave, MD
- Clinical Associate Professor, Hematology and Oncology
Rupali Roy Bhave, MD
- Education
- MD, University of Arizona College of Medicine, 2006
- Residency
- Department of Medicine, University of Virginia Medical Center, 2009
- Positions
- Clinical Associate Professor, Hematology and Oncology
- Departments and Affiliations
- Hematology and Oncology
- Comprehensive Cancer Center
Research
- Efficacy of 10-day decitabine in acute myeloid leukemia. Bouligny IM, Mehta V, Isom S, Ellis LR, Bhave RR, Howard DS, Lyerly S, Manuel M, Dralle S, Powell BL, Pardee TS. Leuk Res. 2021 Apr; 103:106524.
- A Pilot Phase II Study of the Feasibility and Efficacy of Vincristine Sulfate Liposome Injection in Patients With Relapsed or Refractory Acute Myeloid Leukemia. Seegars MB, Woods R, Ellis LR, Bhave RR, Howard DS, Manuel M, Dralle S, Lyerly S, Powell BL, Pardee TS. J Hematol. 2021 Feb; 10(1):1-7.
- Geriatric assessment and survival among older adults receiving postremission therapy for acute myeloid leukemia. Saad M, Loh KP, Tooze JA, Pardee TS, Ellis LR, Powell BL, Bhave RR, Geiger AM, Williamson JD, Kritchevsky S, Klepin HD. Blood. 2020 12; 136(23):2715-2719.
- Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase. Mascarenhas JO, Rampal RK, Kosiorek HE, Bhave R, Hexner E, Wang ES, Gerds A, Abboud CN, Kremyanskaya M, Berenzon D, Odenike O, Farnoud N, Krishnan A, Weinberg RS, McGovern E, Salama ME, Najfeld V, Medina-Martinez JS, Arango Ossa JE, Levine MF, Zhou Y, Sandy L, Heaney ML, Levine RL, Mesa RA, Dueck AC, Hoffman R. Blood Adv. 2020 10; 4(20):5246-5256.
- Prostaglandin E1 and Its Analog Misoprostol Inhibit Human CML Stem Cell Self-Renewal via EP4 Receptor Activation and Repression of AP-1. Li F, He B, Ma X, Yu S, Bhave RR, Lentz SR, Tan K, Guzman ML, Zhao C, Xue HH. Cell Stem Cell. 2017 09; 21(3):359-373.e5.